Evidence map›Paper›PMID 33033993›Full record

ArticleCellular and molecular neurobiology2021

Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.

Ankita Narayan, Amanda Hunkele, Jin Xu, Daniel L Bassoni, Gavril W Pasternak, Ying-Xian Pan

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Interactive effects of morphine and the HIV integrase inhibitor, cabotegravir, in male and female mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ankita NarayanDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0001-9485-8996
Amanda HunkeleDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-2551-3035
Jin XuDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0001-5506-4333
Daniel L BassoniEurofins DiscoverX, Fremont, CA, USA.ORCID http://orcid.org/0000-0003-4853-0265
Gavril W PasternakDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0003-0060-6996
Ying-Xian PanDepartment of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. pany@mskcc.org.ORCID http://orcid.org/0000-0002-4006-8304
Memorial Sloan Kettering Cancer Center · USDiscoveRx (United States) · USRutgers, The State University of New Jersey · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
TRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2M
Arylepoxamides: A new class of potent, safer analgesicsUG3DA048379 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2019 to 2021
$6.8M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR01DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1991 to 2022
$6.0M
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actionsR01DA042888 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2017 to 2021
$1.9M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR37DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PASTERNAK, GAVRIL W · 1996 to 2004
$1.5M
Exploring functions of mu opioid receptor carboxyl termini by gene targetingR21DA029244 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2010 to 2011
$522k
Mapping mu agonist-induced receptor-protein interactions for OPRM1 7TM variantsR21DA046714 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2018 to 2019
$502k
Exploring function of mu opioid receptor splice variants in rat by gene targetingR21DA040858 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2016 to 2017
$471k
NCI NIH HHS CA008748NCI NIH HHS P30 CA008748NIDA NIH HHS DA007242NIDA NIH HHS DA042888NIDA NIH HHS DA046714NIDA NIH HHS R01 DA007242NIDA NIH HHS R01 DA042888NIDA NIH HHS R21 DA029244NIDA NIH HHS R21 DA040858NIDA NIH HHS R21 DA046714NIDA NIH HHS R37 DA007242NIDA NIH HHS T32 DA007242NIDA NIH HHS UG3 DA048379
6 · The paper itself

Abstract

The biased signaling has been extensively studied in the original mu opioid receptor (MOR-1), particularly through G protein and β-arrestin2 signaling pathways. The concept that the G protein pathway is often linked to the therapeutic effect of the drug, while the β-arrestin pathway is associated to the side effects has been proposed to develop biased analgesic compounds with limited side-effects associated with traditional opiates. The mu opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms that are conserved from rodent to human. One type of the Oprm1 splice variants are the full-length 7 transmembrane (7TM) C-terminal splice variants, which have identical receptor structures including entire binding pocket, but contain a different intracellular C-terminal tail resulted from 3' alternative splicing. Increasing evidence suggest that these full-length 7TM C-terminal variants play important roles in mu opioid pharmacology, raising questions regarding biased signaling at these multiple C-terminal variants. In the present study, we investigated the effect of different C-terminal variants on mu agonist-induced G protein coupling, β-arrestin2 recruitment, and ultimately, signaling bias. We found that mu agonists produced marked differences in G protein activation and β-arrestin2 recruitment among various C-terminal variants, leading to biased signaling at various level. Particularly, MOR-1O, an exon 7-associated variant, showed greater β-arrestin2 bias for most mu agonists than MOR-1, an exon 4-associated variant. Biased signaling of G protein-coupled receptors has been defined by evidences that different agonists can produce divergent signaling transduction pathways through a single receptor. Our findings that a single mu agonist can induce differential signaling through multiple 7TM splice variants provide a new perspective on biased signaling at least for Oprm1, which perhaps is important for our understanding of the complex mu opioid actions in vivo where all the 7TM splice variants co-exist.

Indexed as

Alternative SplicingAmino Acid SequenceAnalgesics, OpioidAnimalsCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugGuanosine 5'-O-(3-Thiotriphosphate)HEK293 CellsHumansNaltrexoneProtein BindingReceptors, Opioid, muSignal TransductionAnalgesics, OpioidGuanosine 5'-O-(3-Thiotriphosphate)iodobenzoylnaltrexamideNaltrexoneOPRM1 protein, humanOprm protein, mouseReceptors, Opioid, muBeta-arrestinBiased signalingG-proteinMu opioid receptorSplicing

Identifiers

PMID33033993
PMCPMC8026774
OpenAlexW4206801413

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.